Myopathy secondary to empagliflozin therapy in type 2 diabetes
Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycaemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in conjunction with metformin) in patients with type 2 diabetes and establi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2020-04-01
|
| Series: | Endocrinology, Diabetes & Metabolism Case Reports |
| Online Access: | https://doi.org/10.1530/EDM-20-0017 |